Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Leukemia & Lymphoma|May 22, 2026
Long-term outcomes of ropeginterferon alfa-2b-njft in polycythemia vera: a review of safety, efficacy, and potential disease modificationGhaith Abu-Zeinah, Brandi ReevesThrombosis Research|May 22, 2016
Astrocyte tissue factor controls CNS hemostasis and autoimmune inflammationShaobin Wang, Brandi Reeves, Rafal PawlinskiNeurobiology of Disease|December 2, 2004
The impact of excitotoxic blockade on the evolution of injury following combined mechanical and hypoxic insults in primary rat neuronal cultureTodd F Glass, Brandi Reeves, Frank R SharpNeuroscience Letters|July 23, 2002
Modeling both the mechanical and hypoxic features of traumatic brain injury in vitro in ratsTodd F Glass, Brandi Reeves, Frank R SharpBritish Journal of Haematology|January 6, 2021
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1Sara Bringhen, Peter M Voorhees, Torben Plesner, et al.JCI Insight|August 5, 2016
Protective and detrimental effects of neuroectodermal cell-derived tissue factor in mouse models of strokeShaobin Wang, Brandi Reeves, Erica M Sparkenbaugh, et al.Journal of Thrombosis and Haemostasis : JTH|June 24, 2020
High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell diseaseErica M Sparkenbaugh, Malgorzata Kasztan, Michael W Henderson, et al.Blood Advances|February 19, 2021
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFINPeter M Voorhees, Cesar Rodriguez, Brandi Reeves, et al.Blood Cancer Journal|March 22, 2019
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studySuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.The Lancet. Haematology|March 28, 2020
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 studyPaul G Richardson, Sara Bringhen, Peter Voorhees, et al.Pageof 3